"Ganciclovir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
| Descriptor ID |
D015774
|
| MeSH Number(s) |
D03.633.100.759.758.399.454.250.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ganciclovir".
Below are MeSH descriptors whose meaning is more specific than "Ganciclovir".
This graph shows the total number of publications written about "Ganciclovir" by people in this website by year, and whether "Ganciclovir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 3 | 6 |
| 1996 | 2 | 2 | 4 |
| 1997 | 1 | 2 | 3 |
| 1998 | 1 | 2 | 3 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 5 | 6 |
| 2001 | 2 | 2 | 4 |
| 2002 | 0 | 3 | 3 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 3 | 4 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ganciclovir" by people in Profiles.
-
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2024 05 03; 5:CD003774.
-
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. J Infect Dis. 2024 Feb 14; 229(2):413-421.
-
Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial. J Pediatr. 2024 May; 268:113934.
-
Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients. Am J Transplant. 2023 12; 23(12):1961-1971.
-
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clin Infect Dis. 2022 09 10; 75(4):690-701.
-
Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium. Clin Microbiol Infect. 2023 Jan; 29(1):44-50.
-
Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy. J Pediatric Infect Dis Soc. 2022 Jan 27; 11(1):16-23.
-
Multiplexed drug-based selection and counterselection genetic manipulations in Drosophila. Cell Rep. 2021 09 14; 36(11):109700.
-
Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. Am J Transplant. 2022 01; 22(1):187-198.
-
I Can't See. J Pediatr Ophthalmol Strabismus. 2019 Mar 19; 56(2):71.